These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 15225171)

  • 41. Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: results of a 26-week trial.
    Pavelka K; Recker DP; Verburg KM
    Rheumatology (Oxford); 2003 Oct; 42(10):1207-15. PubMed ID: 12810937
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo.
    Bensen WG; Zhao SZ; Burke TA; Zabinski RA; Makuch RW; Maurath CJ; Agrawal NM; Geis GS
    J Rheumatol; 2000 Aug; 27(8):1876-83. PubMed ID: 10955327
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of acute low back pain with the COX-2-selective anti-inflammatory drug nimesulide: results of a randomized, double-blind comparative trial versus ibuprofen.
    Pohjolainen T; Jekunen A; Autio L; Vuorela H
    Spine (Phila Pa 1976); 2000 Jun; 25(12):1579-85. PubMed ID: 10851109
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cyclo-oxygenase-1/cyclo-oxygenase-2 non selective non-steroidal anti-inflammatory drugs: epidemiology of gastrointestinal events.
    Lanas A
    Dig Liver Dis; 2001 Dec; 33 Suppl 2():S29-34. PubMed ID: 11827360
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease: a reappraisal.
    Baigent C; Patrono C
    Arthritis Rheum; 2003 Jan; 48(1):12-20. PubMed ID: 12528099
    [No Abstract]   [Full Text] [Related]  

  • 46. Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen.
    Lanza FL; Rack MF; Simon TJ; Quan H; Bolognese JA; Hoover ME; Wilson FR; Harper SE
    Aliment Pharmacol Ther; 1999 Jun; 13(6):761-7. PubMed ID: 10383505
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial.
    Yeomans ND; Graham DY; Husni ME; Solomon DH; Stevens T; Vargo J; Wang Q; Wisniewski LM; Wolski KE; Borer JS; Libby P; Lincoff AM; Lüscher TF; Bao W; Walker C; Nissen SE;
    Aliment Pharmacol Ther; 2018 Jun; 47(11):1453-1463. PubMed ID: 29667211
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gastrointestinal toxicity of over-the-counter analgesics.
    Dajani EZ
    Am J Gastroenterol; 1998 Jul; 93(7):1020-2. PubMed ID: 9672322
    [No Abstract]   [Full Text] [Related]  

  • 49. A randomized, double-blind, crossover comparative endoscopy study on the gastroduodenal tolerability of a highly specific cyclooxygenase-2 inhibitor, flosulide, and naproxen.
    Bjarnason I; Macpherson A; Rotman H; Schupp J; Hayllar J
    Scand J Gastroenterol; 1997 Feb; 32(2):126-30. PubMed ID: 9051872
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials.
    Hawkey CJ; Laine L; Harper SE; Quan HU; Bolognese JA; Mortensen E;
    Aliment Pharmacol Ther; 2001 Oct; 15(10):1593-601. PubMed ID: 11563999
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A 6-week, multicentre, randomised, double-blind, double-dummy, active-controlled, clinical safety study of lumiracoxib and rofecoxib in osteoarthritis patients.
    Stricker K; Yu S; Krammer G
    BMC Musculoskelet Disord; 2008 Sep; 9():118. PubMed ID: 18778469
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lumiracoxib in the management of osteoarthritis and acute pain.
    Bannwarth B; Bérenbaum F
    Expert Opin Pharmacother; 2007 Jul; 8(10):1551-64. PubMed ID: 17661736
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin.
    Catella-Lawson F; Reilly MP; Kapoor SC; Cucchiara AJ; DeMarco S; Tournier B; Vyas SN; FitzGerald GA
    N Engl J Med; 2001 Dec; 345(25):1809-17. PubMed ID: 11752357
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A comparison of the blood pressure changes of lumiracoxib with those of ibuprofen and naproxen.
    Farkouh ME; Verheugt FW; Ruland S; Kirshner H; Jeger R; Gitton X; Krammer G; Stricker K; Sallstig P; Mellein B; Matchaba P; Chesebro JH
    J Clin Hypertens (Greenwich); 2008 Aug; 10(8):592-602. PubMed ID: 18772641
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis.
    Goldstein JL; Correa P; Zhao WW; Burr AM; Hubbard RC; Verburg KM; Geis GS
    Am J Gastroenterol; 2001 Apr; 96(4):1019-27. PubMed ID: 11316141
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis.
    White WB; Strand V; Roberts R; Whelton A
    Am J Ther; 2004; 11(4):244-50. PubMed ID: 15266215
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Upper gastrointestinal safety evaluation of parecoxib sodium, a new parenteral cyclooxygenase-2-specific inhibitor, compared with ketorolac, naproxen, and placebo.
    Harris SI; Kuss M; Hubbard RC; Goldstein JL
    Clin Ther; 2001 Sep; 23(9):1422-8. PubMed ID: 11589257
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lumiracoxib (Prexige): a new selective COX-2 inhibitor.
    Mysler E
    Int J Clin Pract; 2004 Jun; 58(6):606-11. PubMed ID: 15311562
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model.
    Umar A; Boisseau M; Yusup A; Upur H; Bégaud B; Moore N
    Fundam Clin Pharmacol; 2004 Oct; 18(5):559-63. PubMed ID: 15482377
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
    Weir MR; Sperling RS; Reicin A; Gertz BJ
    Am Heart J; 2003 Oct; 146(4):591-604. PubMed ID: 14564311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.